Why BioNTech (BNTX) Is Up 9.2% After Strong Phase 2 HER2 ADC Data In Endometrial Cancer

Earlier in April 2026, BioNTech reported positive primary Phase 2 results for its HER2‑targeted antibody-drug conjugate trastuzumab pamirtecan in previously treated, advanced endometrial cancer, ...

BioNTech SE (BNTX) PT Slightly Raised as Morgan Stanley Updates Biopharma Coverage Models

We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. BioNTech SE is among the best biotech ...
MedCity News

BMS Buys Into BioNTech Bispecific Antibody, Putting Up $1.5B to Collaborate in Multiple Cancers

BioNTech’s oncology strategy centers on a bispecific antibody that the company envisions as the backbone of many potential drug combinations for many types of cancer. Bristol Myer Squibb is buying ...
Nasdaq

BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025

MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...
Nasdaq

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next milestone in the execution of its ...
Seeking Alpha

BioNTech's Low Valuation, Many Shots On Goal Make It A Buy

BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab, a bispecific antibody similar to BioNTech's PM8002. BioNTech's PM8002 antibody is similar to Summit's ...